

## **Entrectinib for treating NTRK fusion-positive solid tumours**

Technology appraisal guidance [TA644]

### **Applications to the Cancer Drugs Fund**

**25 June 2020 – 30 April 2025**

#### **Background**

Entrectinib became available within the Cancer Drugs Fund (CDF) from 25 June 2020. This reporting period is for applications for use made between 25 June 2020 and 30 April 2025. A snapshot of the Systemic Anti-Cancer Therapy (SACT) data was taken on 2 August 2025 and made available for analysis on 20 August 2025 and includes SACT activity up to 30 April 2025.

#### **Summary**

Table 1 presents the number of applications to the CDF which were made between 25 June 2020 and 30 April 2025. We also present the number of applicants/patients with reported SACT activity and their treatment outcomes to 30 April 2025.

**Table 1:** Entrectinib applications made to the CDF between 25 June 2020 and 30 April 2025; SACT data to 30 April 2025.

	<b>Numbers of patients</b>	<b>Comments</b>
<b>Applications</b>		
Applications for new use of entrectinib: 25 June 2020 to 30 April 2025	12	<b>Note:</b> <i>this is the baseline for this reporting window.</i>
<b>Missing in SACT</b>		
Missing in SACT by 30 April 2025	2	
<b>Reason for missing treatment data in SACT</b>		
Patient died before treatment	2	<b>Note:</b> <i>2 patients died before treatment, these were confirmed by the relevant trust by the NHS England data liaison team.</i>
<b>Reported in SACT</b>		
Reported in SACT by 30 April 2025	10	
<b>Outcomes (for the 10 patients with SACT data)</b>		
Stopped treatment: Progressive disease during chemotherapy	3	
Stopped treatment: Patient choice	1	
Patient died	2	
Patients still on treatment	4	